IBRX Stock Overview
A clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
ImmunityBio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.56 |
| 52 Week High | US$10.53 |
| 52 Week Low | US$2.50 |
| Beta | -0.43 |
| 1 Month Change | -43.86% |
| 3 Month Change | -25.36% |
| 1 Year Change | -47.00% |
| 3 Year Change | -58.97% |
| 5 Year Change | n/a |
| Change since IPO | -93.38% |
Recent News & Updates
Recent updates
ImmunityBio's Cash Burn And Dilution Dampen Anktiva's Potential
Dec 11ImmunityBio: Continued Volatility Suggests Further Upside Potential, But I'd Be Careful
Oct 25ImmunityBio: Moving The Needle
Oct 07ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt
Sep 21ImmunityBio: Anktiva's Launch Progresses - Bladder Cancer Drug May Be 'Real Deal'
Aug 14ImmunityBio: All Eyes On Execution Now (Rating Upgrade)
Jul 09ImmunityBio: Positive Near-Term Catalysts Create Strong Short Squeeze Potential
Jun 25ImmunityBio: Anktiva's Launch Demands A Reassessment
Jun 06ImmunityBio Lights Up: Anktiva's FDA Nod Shakes Up Bladder Cancer Battle
Apr 23ImmunityBio: Financial And Regulatory Risks Outweigh Anktiva's Promise
Feb 27ImmunityBio: Buy Low Now Vs. Buy High Later
Feb 11ImmunityBio: PDUFA Pending
Oct 17ImmunityBio: Compelling Data In Bladder Cancer, Yet Funding Issues Remain
Aug 07Shareholder Returns
| IBRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.8% | -2.7% | -2.6% |
| 1Y | -47.0% | -6.2% | 23.1% |
Return vs Industry: IBRX underperformed the US Biotechs industry which returned -6.2% over the past year.
Return vs Market: IBRX underperformed the US Market which returned 23.1% over the past year.
Price Volatility
| IBRX volatility | |
|---|---|
| IBRX Average Weekly Movement | 17.7% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IBRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: IBRX's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 672 | Rich Adcock | immunitybio.com |
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company’s platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme.
ImmunityBio, Inc. Fundamentals Summary
| IBRX fundamental statistics | |
|---|---|
| Market cap | US$1.78b |
| Earnings (TTM) | -US$587.79m |
| Revenue (TTM) | US$7.33m |
243.3x
P/S Ratio-3.0x
P/E RatioIs IBRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBRX income statement (TTM) | |
|---|---|
| Revenue | US$7.33m |
| Cost of Revenue | US$0 |
| Gross Profit | US$7.33m |
| Other Expenses | US$595.13m |
| Earnings | -US$587.79m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.84 |
| Gross Margin | 100.00% |
| Net Profit Margin | -8,016.83% |
| Debt/Equity Ratio | -131.0% |
How did IBRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 02:11 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ImmunityBio, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Kolbert | D. Boral Capital LLC. |
| Dingding Shi | Jefferies LLC |
| Joseph Catanzaro | Piper Sandler Companies |